Aplegin (carnitine-chloride) treatment of brain hypoxical lesions

Therapelutic results are given of aplegin (carnitine-chloride) treatment of 82 patients with critical ischemic insult and of 7 patients with prolonged coma of hypoxic, toxic and traumatic genesis. Significant acceleration and more complete restoration of neurologic functions were observed in comparison with the control group when aplegin was administered; the latter much depended on the time of beginning of treatment and was as more complete, as more quick was aplegin injection, beginning from the disease onset. Aplegin action mechanism is explained by the carnitine property to activate fat acids metabolism, to restore energy deficit in hypoxia, to increase reparative processes in nervous tissue and prevent brain from toxic enfluence of decay products and neurotoxins.